Targeting RAGE prevents muscle wasting and prolongs survival in cancer cachexia.

ABSTRACT:

Background

Cachexia, a multifactorial syndrome affecting more than 50% of patients with advanced cancer and responsible for ~20% of cancer-associated deaths, is still a poorly understood process without a standard cure available. Skeletal muscle atrophy caused by systemic inflammation is a major clinical feature of cachexia, leading to weight loss, dampening patients' quality of life, and reducing patients' response to anticancer therapy. RAGE (receptor for advanced glycation end-products) is a multiligand receptor of the immunoglobulin superfamily and a mediator of muscle regeneration, inflammation, and cancer.

Methods

By using murine models consisting in the injection of colon 26 murine adenocarcinoma (C26-ADK) or Lewis lung carcinoma (LLC) cells in BALB/c and C57BL/6 or A

SUBMITTER: Chiappalupi S 

PROVIDER: S-EPMC7432590 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature